Aposense Ltd. (TASE: APOS) is expanding to France the Phase II clinical trial of its EarliTest product for the early assessments of tumors of brain, lung, and cervix cancers. The system is based on the molecular imaging system developed by the company. The product is currently undergoing a multicenter efficacy trial in Israel and the US.
The French Agency for the Health Security of Health Products (AFSSAPS) has approved the adding of two medical centers to the trial, bringing the number of participating hospitals to 16.
Earlier this year, the company added Hadassah Ein Kerem Medical Center and the Rabin Medical Center (Beilinson Hospital) to the trial. The company believes that increasing the number of participating hospitals will enable it to complete recruitment for the clinical trial for the three indications by the end of this year.
The company also believes that expanding the clinical trial to Europe will facilitate obtaining EU regulatory approval for the EarliTest, opening a new market to the company.
Participating US hospitals, including Sloan Kettering, Harvard Medical School, Mount Sinai School of Medicine, University of Pittsburgh Medical Center, and the University of Pennsylvania Medical Center.
Aposense's share price was unchanged by early afternoon at NIS 11.02, giving a market cap of NIS 292 million.
No comments:
Post a Comment